Black Diamond Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for BDTX, updated each market day.
BDTX AI Sentiment
AI predicts Black Diamond Therapeutics, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Black Diamond Therapeutics, Inc. Common Stock
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Sector
Exchange
Market Cap
$147,804,975
Cap Tier
Employees
21
Headquarters
CAMBRIDGE, MA
Listed Since
Jan. 30, 2020
BDTX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
BDTX Volatility
Black Diamond Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
